These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9748124)

  • 1. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
    Geisler J; King N; Anker G; Ornati G; Di Salle E; Lønning PE; Dowsett M
    Clin Cancer Res; 1998 Sep; 4(9):2089-93. PubMed ID: 9748124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
    Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
    Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
    Geisler J; Haynes B; Anker G; Dowsett M; Lønning PE
    J Clin Oncol; 2002 Feb; 20(3):751-7. PubMed ID: 11821457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
    Geisler J; Haynes B; Ekse D; Dowsett M; Lønning PE
    J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):27-34. PubMed ID: 17350249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.
    Bertelsen BE; Almås B; Fjermeros K; Viste K; Geisler SB; Sauer T; Selsås K; Geisler J
    Breast Cancer Res Treat; 2024 Jul; 206(2):347-358. PubMed ID: 38649619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
    Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
    Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
    Miller WR; Dixon JM
    Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
    Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
    J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
    Lombardi P
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):326-37. PubMed ID: 12084475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exemestane in postmenopausal women with early or advanced breast cancer: a review.
    Bertelli G; Gangadhara S
    Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exemestane (FCE 24304), a new steroidal aromatase inhibitor.
    di Salle E; Ornati G; Giudici D; Lassus M; Evans TR; Coombes RC
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):137-43. PubMed ID: 1525055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women.
    van der Wall E; Donker TH; de Frankrijker E; Nortier HW; Thijssen JH; Blankenstein MA
    Cancer Res; 1993 Oct; 53(19):4563-6. PubMed ID: 8402628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.
    Geisler J; Lundgren S; Berntsen H; Greaves JL; Lønning PE
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2687-93. PubMed ID: 9709932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exemestane in advanced breast cancer.
    Buzdar A
    Anticancer Drugs; 2000 Sep; 11(8):609-16. PubMed ID: 11081451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study.
    Paridaens R; Thomas J; Wildiers J; Vermeiren P; Lobelle JP; di Salle E; Ornati G; Zurlo MG; Polli A; Lanzalone S; de Belder K
    Anticancer Drugs; 1998 Sep; 9(8):675-83. PubMed ID: 9823425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
    Evans TR; Di Salle E; Ornati G; Lassus M; Benedetti MS; Pianezzola E; Coombes RC
    Cancer Res; 1992 Nov; 52(21):5933-9. PubMed ID: 1394219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.
    Jones S; Vogel C; Arkhipov A; Fehrenbacher L; Eisenberg P; Cooper B; Honig S; Polli A; Whaley F; di Salle E; Tiffany J; Consonni A; Miller L
    J Clin Oncol; 1999 Nov; 17(11):3418-25. PubMed ID: 10550136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local endocrine effects of aromatase inhibitors within the breast.
    Miller WR; Dixon JM
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):93-102. PubMed ID: 11850212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
    Clemett D; Lamb HM
    Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
    Rivera E; Valero V; Francis D; Asnis AG; Schaaf LJ; Duncan B; Hortobagyi GN
    Clin Cancer Res; 2004 Mar; 10(6):1943-8. PubMed ID: 15041710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.